Sio Gene Therapies Stock (NASDAQ:SIOX)
Previous Close
$NaN
52W Range
$0.41 - $0.41
50D Avg
-
200D Avg
-
Market Cap
$30.70M
Avg Vol (3M)
$62.41K
Beta
1.08
Div Yield
$0.43 (104.82%)
SIOX Company Profile
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.
SIOX Performance
Peer Comparison
| Ticker | Company |
|---|---|
| NUVB | Nuvation Bio Inc. |
| MGTA | Dianthus Therapeutics, Inc. |
| MNPR | Monopar Therapeutics Inc. |
| XOMA | XOMA Corporation |
| ALGS | Aligos Therapeutics, Inc. |
| SABS | SAB Biotherapeutics, Inc. |
| CTMX | CytomX Therapeutics, Inc. |
| SRZN | Surrozen, Inc. |
| VCNX | Vaccinex, Inc. |
| ASMB | Assembly Biosciences, Inc. |
| RZLT | Rezolute, Inc. |
| TPST | Tempest Therapeutics, Inc. |
| VINC | Vincerx Pharma, Inc. |
| TARA | Protara Therapeutics, Inc. |
| MOLN | Molecular Partners AG |
| NLTX | Neurogene Inc. |
| ABIO | ARCA biopharma, Inc. |
| TIL | Instil Bio, Inc. |